The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway

Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy

(2015) Chiara Melloni et al.  

Should Proton Pump Inhibitors Be Withheld From Patients Taking Clopidogrel?

(2015) Peter B. Berger  

Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans

(2015) EK Tarkiainen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy

(2015) Chiara Melloni et al.   Circulation-Cardiovascular Quality and Outcomes

Should Proton Pump Inhibitors Be Withheld From Patients Taking Clopidogrel?

(2015) Peter B. Berger   Circulation-Cardiovascular Quality and Outcomes

Platelet Function Tests: Why They Fail to Guide Personalized Antithrombotic Medication

(2015) D. A. Gorog et al.   Journal of the American Heart Association

High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization

(2014) Gilles Montalescot et al.   CIRCULATION

Mechanisms of Plaque Formation and Rupture

(2014) Jacob Fog Bentzon et al.   CIRCULATION RESEARCH

Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes

(2014) Deepak L. Bhatt et al.   CIRCULATION RESEARCH

Non-antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with differentCYP2C19genotype

(2014) Yin-Zhuang Zhang et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy

(2014) B. S. Karon et al.   CLINICAL CHEMISTRY

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users

(2014) Ruben L. Osnabrugge et al.   GENETICS IN MEDICINE

Proton pump inhibitor use represents an independent risk factor for myocardial infarction

(2014) Chia-Jen Shih et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Variability of Individual Platelet Reactivity Over Time in Patients Treated With Clopidogrel

(2014) Willibald Hochholzer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use

(2013) Mette Charlot   ANNALS OF INTERNAL MEDICINE

Personalized antiplatelet therapy: The wrong approach?

(2013) Jean-Philippe Collet et al.   Archives of Cardiovascular Diseases

Thiolactone Sulfoxides as New Reactive Metabolites Acting as Bis-Electrophiles: Implication in Clopidogrel and Prasugrel Bioactivation

(2013) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel

(2013) M T Holmberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

(2013) Stefan Agewall et al.   EUROPEAN HEART JOURNAL

Platelet Function and Genetic Testing

(2013) Dominick J. Angiolillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function

(2013) Andrew L. Frelinger et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of clopidogrel and proton pump inhibitors after a serious acute coronary event: Risk of coronary events and peptic ulcer bleeding

(2013) Luis Rodríguez et al.   THROMBOSIS AND HAEMOSTASIS

Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping

(2013) Pierre Fontana et al.   Journal of the American Heart Association

Metabolic Activation of Prasugrel: Nature of the Two Competitive Pathways Resulting in the Opening of Its Thiophene Ring

(2012) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

In Vitro Biotransformation Studies of 2-Oxo-clopidogrel: Multiple Thiolactone Ring-Opening Pathways Further Attenuate Prodrug Activation

(2012) Yaoqiu Zhu et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Antiplatelet Therapy and Proton Pump Inhibition

(2012) George V. Moukarbel et al.   CIRCULATION

Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events

(2012) Guillaume Paré et al.   Circulation-Cardiovascular Genetics

Paraoxonase 1 Q192R Variant and Clopidogrel Efficacy

(2012) Joshua P. Lewis et al.   Circulation-Cardiovascular Genetics

Antiplatelet therapy and proton pump inhibition

(2012) Jeremiah P. Depta et al.   CURRENT OPINION IN CARDIOLOGY

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review

(2012) Jeroen Jaspers Focks et al.   HEART

No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Meta-analysis

(2012) Chun Shing Kwok et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin

(2012) Yan Liang et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation

(2012) Yaoqiu Zhu et al.   ACS Medicinal Chemistry Letters

Review article: proton pump inhibitors with clopidogrel - evidence for and against a clinically-important interaction

(2011) B. R. Disney et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Meta-Analysis of Impact of Proton Pump Inhibitors on Antiplatelet Effect of Clopidogrel

(2011) Mao Chen et al.   Cardiovascular Therapeutics

Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer

(2011) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction

(2011) Tabassome Simon et al.   CIRCULATION

CYP2C19 Genotype and Proton Pump Inhibitors in Clopidogrel-Treated Patients

(2011) Michelle L. O'Donoghue   CIRCULATION

Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement

(2011) Dietmar Trenk et al.   Circulation-Cardiovascular Genetics

Unraveling the Pharmacogenetics of Clopidogrel

(2011) Jaapjan D. Snoep   Circulation-Cardiovascular Interventions

Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature

(2011) Lauren B. Gerson et al.   DIGESTIVE DISEASES AND SCIENCES

Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel

(2011) Chun Shing Kwok et al.   DRUG SAFETY

Proton Pump Inhibitor Co-therapy With Clopidogrel: Is There GI Benefit or Cardiovascular Harm?

(2011) Loren Laine   GASTROENTEROLOGY

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

(2011) Michael V. Holmes et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacogenomics and Clopidogrel

(2011) Steven E. Nissen   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors

(2011) Paolo Ortolani et al.   Journal of Cardiovascular Medicine

Usefulness of Clopidogrel to Protect Against Diabetes-Induced Vascular Damage

(2010) John A. McClung et al.   AMERICAN JOURNAL OF CARDIOLOGY

The potential interaction between clopidogrel and proton pump inhibitors: a systematic review

(2010) Joao Paulo de Aquino Lima et al.   BMC Medicine

ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

(2010) et al.   CIRCULATION

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”

(2010) et al.   CIRCULATION

Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis

(2010) Ping–I. Hsu et al.   GASTROENTEROLOGY

Clopidogrel and Endothelial Injury After Percutaneous Coronary Interventions

(2010) Goran Rudež et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Level of Adenosine Diphosphate Receptor P2Y12 Blockade During Percutaneous Coronary Intervention Predicts the Extent of Endothelial Injury, Assessed by Circulating Endothelial Cell Measurement

(2010) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Case for Routine Genotyping in Dual-Antiplatelet Therapy

(2010) Samir B. Damani et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

(2010) Jean-Sébastien Hulot et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Paraoxonase-1 is a major determinant of clopidogrel efficacy

(2010) Heleen J Bouman et al.   NATURE MEDICINE

Clopidogrel with or without Omeprazole in Coronary Artery Disease

(2010) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel

(2009) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

(2009) Jeremy A. Rassen et al.   CIRCULATION

Proton Pump Inhibitors and Clopidogrel

(2009) David N. Juurlink   CIRCULATION

Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention

(2009) Ekta Gupta et al.   DIGESTIVE DISEASES AND SCIENCES

Risk of combining PPIs with thienopyridines: fact or fiction?

(2009) Dirk Sibbing et al.   LANCET

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

(2009) Michelle L O'Donoghue et al.   LANCET

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin

(2008) Martine Gilard et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2008) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

(2008) Tabassome Simon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

(2008) Nagy A Farid et al.   PHARMACOTHERAPY

Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin

(2008) J.-E. Park et al.   XENOBIOTICA